Protagonist Therapeutics Ownership | Who Owns Protagonist Therapeutics?


OverviewForecastRevenueFinancialsChart

Protagonist Therapeutics Ownership Summary


Protagonist Therapeutics is owned by 33.97% institutional investors, 1.01% insiders, and 65.02% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 14.81% of PTGX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.93% of its assets in Protagonist Therapeutics shares.

PTGX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockProtagonist Therapeutics33.97%1.01%65.02%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de9.40M14.81%$624.72M
Farallon capital management6.20M9.76%$411.60M
Blackrock5.76M9.39%$199.52M
Rtw investments, lp5.76M9.06%$382.39M
Vanguard group4.26M6.70%$282.81M
State street3.17M4.98%$210.30M
Bvf inc/il2.56M4.03%$170.12M
Johnson & johnson2.45M3.86%$162.70M
Wellington management group llp1.91M3.00%$126.78M
Ubs group1.90M2.99%$125.95M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Johnson & johnson2.45M32.30%$162.70M
Lynx1 capital management lp700.01K9.47%$46.50M
Aquilo capital management81.69K7.08%$3.95M
Bvf inc/il2.56M6.90%$170.12M
Adar1 capital management989.18K6.17%$65.71M
Rtw investments, lp5.76M4.71%$382.39M
Commodore capital lp1.02M3.32%$68.09M
Deep track capital, lp1.72M3.18%$113.97M
Birchview capital, lp48.00K2.41%$3.19M
Mangrove partners478.41K2.35%$31.78M

Top Buyers

HolderShares% AssetsChange
Marshall wace, llp1.09M0.07%1.09M
Wellington management group llp1.91M0.02%870.71K
Woodline partners lp1.44M0.45%491.36K
Pictet asset management sa751.98K0.04%456.38K
Colony group448.99K0.05%448.99K

Top Sellers

HolderShares% AssetsChange
Pacer advisors---1.88M
Deep track capital, lp1.72M3.18%-1.53M
Fairmount funds management---931.89K
Bvf inc/il2.56M6.90%-650.13K
Ubs group1.90M0.02%-605.24K

New Positions

HolderShares% AssetsChangeValue
Marshall wace, llp1.09M0.07%1.09M$72.11M
Eagle asset management357.63K0.07%357.63K$12.59M
Logos global management lp300.00K1.79%300.00K$19.93M
Duquesne family office159.70K0.26%159.70K$10.61M
Millennium management134.27K0.00%134.27K$6.49M

Sold Out

HolderChange
Tfc financial management-1.00
Ifp advisors-5.00
Mendota financial group-6.00
Federated hermes-7.00
Nelson, van denburg & campbell wealth management group-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025140-48.91%21,573,409-68.80%330.29%55-67.26%60-20.00%
Jun 30, 2025279-3.79%70,876,6488.54%1111.04%1673.73%78-13.33%
Mar 31, 202519-92.31%15,761,655-75.08%250.24%12-91.18%5-93.33%
Dec 31, 2024147-40.49%31,832,545-48.43%510.52%84-45.81%42-35.38%
Sep 30, 202424627.46%61,406,0774.02%991.07%15469.23%65-7.14%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.69M5.93%-
Vanguard Total Stock Mkt Idx Inv1.94M3.12%-41.38K
Vanguard US Total Market Shares ETF1.87M3.05%129.62K
Pacer US Small Cap Cash Cows 100 ETF1.61M2.63%-11.71K
iShares Russell 2000 ETF1.40M2.25%-
SPDR® S&P Biotech ETF983.05K1.58%2.19K
T. Rowe Price Health Sciences882.85K1.42%197.40K
UBS: US Equity Small Cap Growth744.87K1.25%-
Vanguard Institutional Extnd Mkt Idx Tr665.61K1.07%-291.62K
Fidelity Small Cap Index584.22K0.94%-18.06K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 17, 2025MOLINA ARTURO MD Chief Medical OfficerSell$229.90K
Oct 10, 2025Waddill William D.-Sell$277.00K
Oct 10, 2025Waddill William D.-Sell$702.48K
Sep 22, 2025Waddill William D.-Sell$257.00K
Aug 27, 2025Waddill William D.-Sell$237.00K

Insider Transactions Trends


DateBuySell
2025 Q4-3
2025 Q3-6
2025 Q2-3
2025 Q1-8
2024 Q4-8

PTGX Ownership FAQ


Who Owns Protagonist Therapeutics?

Protagonist Therapeutics shareholders are primarily institutional investors at 33.97%, followed by 1.01% insiders and 65.02% retail investors. The average institutional ownership in Protagonist Therapeutics's industry, Biotech Stocks , is 45.22%, which Protagonist Therapeutics falls below.

Who owns the most shares of Protagonist Therapeutics?

Protagonist Therapeutics’s largest shareholders are Blackrock funding, inc. /de (9.4M shares, 14.81%), Farallon capital management (6.2M shares, 9.76%), and Blackrock (5.76M shares, 9.39%). Together, they hold 33.96% of Protagonist Therapeutics’s total shares outstanding.

Does Blackrock own Protagonist Therapeutics?

Yes, BlackRock owns 9.39% of Protagonist Therapeutics, totaling 5.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 199.52M$. In the last quarter, BlackRock increased its holdings by 188.63K shares, a 3.39% change.

Who is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested?

Johnson & johnson is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested, with 32.30% of its assets in 2.45M Protagonist Therapeutics shares, valued at 162.7M$.

Who is the top mutual fund holder of Protagonist Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Protagonist Therapeutics shares, with 5.93% of its total shares outstanding invested in 3.69M Protagonist Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools